HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) All Versions of this Article: 0091270008319329v1 48/7/849    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Williams, J. A. Articles by Wrighton, S. A. Search for Related Content PubMed PubMed Citation Articles by Williams, J. A. Articles by Wrighton, S. A. Social Bookmarking                         What's this?

PhRMA White Paper on ADME Pharmacogenomics

From Pfizer Global Research and Development, San Diego, California (Dr Williams) and New London, Connecticut (Dr Johnson); AstraZeneca R&D Mölndal, Mölndal, Sweden (Dr T. Andersson, Dr T. B. Andersson); Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institute, Stocknolm, Sweden (Dr T. B. Andersson); AstraZeneca Pharmaceuticals, Wilmington, Delaware (Dr Edeki); Merck and Co, Inc, Blue Bell, Pennsylvania (Dr Blanchard, Dr Behm); Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, New Jersey (Dr Cohen, Dr Franc, Dr Ricci, Dr Vangala); Eli Lilly and Company, Department of Drug Disposition, Lilly Research Labs, Eli Lilly and Company, Indianapolis, Indiana (Dr Hillgren, Dr Shipley, Dr Wrighton); Abbott Laboratories, Abbott Park, Illinois (Dr Katz, Dr Murray); Millennium Pharmaceuticals, Cambridge, Massachusetts (Dr Milton); and GlaxoSmithKline, Inc, Preclinical Drug Metabolism and Pharmacokinetics, Research Triangle Park, North Carolina (Dr Polli). Dr Murray's current affiliation is Gilead Sciences, Drug Metabolism Department, Foster City, California. Dr Milton's current affiliation is Tempo Pharmaceuticals, Inc, Nonclinical Development, Cambridge, Massachusetts. Dr Vangala's current affiliation is Sai Advantium Pharma Limited, Hinjewadi, Pune, India.

Pharmacogenomic (PGx) research on the absorption, distribution, metabolism, and excretion (ADME) properties of drugs has begun to have impact for both drug development and utilization. To provide a cross-industry perspective on the utility of ADME PGx, the Pharmaceutical Research and Manufacturers of America (PhRMA) conducted a survey of major pharmaceutical companies on their PGx practices and applications during 2003-2005. This white paper summarizes and interprets the results of the survey, highlights the contributions and applications of PGx by industrial scientists as reflected by original research publications, and discusses changes in drug labels that improve drug utilization by inclusion of PGx information. In addition, the paper includes a brief review on the clinically relevant genetic variants of drug-metabolizing enzymes and transporters most relevant to the pharmaceutical industry.

Key Words: Pharmacogenomics • ADME • PhRMA • drug-metabolizing enzymes • genotyping

Address for reprints: J. Andrew Williams, PhD, Pfizer Global Research and Development, 10646 Science Center Drive (CB10), San Diego, CA 92121; e-mail: james.williams2{at}pfizer.com.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?